Meyka Pro banner
Novocure Ltd

Novocure Ltd Fundamental Analysis (NASDAQ: NVCR)

NVCRNASDAQ
HealthcareMedical - Devices
$17.38
$0.21(1.19%)
U.S. Market opens in 2h 52m

Novocure Ltd Fundamental Analysis (NASDAQ: NVCR)

Novocure Ltd (NASDAQ: NVCR) shows moderate financial fundamentals with a PE ratio of -13.61, profit margin of -21.25%, and ROE of -44.00%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 8.28%.

Key Strengths

Cash Position21.85%
PEG Ratio-4.29
Current Ratio2.89

Areas of Concern

ROE-44.00%
Operating Margin-22.08%
We analyze NVCR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -28.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-28.8/100

We analyze NVCR's fundamental strength across five key dimensions:

Efficiency Score

Weak

NVCR struggles to generate sufficient returns from assets.

ROA > 10%
-18.68%

Valuation Score

Excellent

NVCR trades at attractive valuation levels.

PE < 25
-13.61
PEG Ratio < 2
-4.29

Growth Score

Excellent

NVCR delivers strong and consistent growth momentum.

Revenue Growth > 5%
8.28%
EPS Growth > 10%
21.79%

Financial Health Score

Excellent

NVCR maintains a strong and stable balance sheet.

Debt/Equity < 1
0.69
Current Ratio > 1
2.89

Profitability Score

Weak

NVCR struggles to sustain strong margins.

ROE > 15%
-4399.94%
Net Margin ≥ 15%
-21.25%
Positive Free Cash Flow
No

Key Financial Metrics

Is NVCR Expensive or Cheap?

P/E Ratio

NVCR trades at -13.61 times earnings. This suggests potential undervaluation.

-13.61

PEG Ratio

When adjusting for growth, NVCR's PEG of -4.29 indicates potential undervaluation.

-4.29

Price to Book

The market values Novocure Ltd at 6.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.07

EV/EBITDA

Enterprise value stands at -14.29 times EBITDA. This is generally considered low.

-14.29

How Well Does NVCR Make Money?

Net Profit Margin

For every $100 in sales, Novocure Ltd keeps $-21.25 as profit after all expenses.

-21.25%

Operating Margin

Core operations generate -22.08 in profit for every $100 in revenue, before interest and taxes.

-22.08%

ROE

Management delivers $-44.00 in profit for every $100 of shareholder equity.

-44.00%

ROA

Novocure Ltd generates $-18.68 in profit for every $100 in assets, demonstrating efficient asset deployment.

-18.68%

Following the Money - Real Cash Generation

Operating Cash Flow

Novocure Ltd generates limited operating cash flow of $1.50M, signaling weaker underlying cash strength.

$1.50M

Free Cash Flow

Novocure Ltd generates weak or negative free cash flow of $-21.20M, restricting financial flexibility.

$-21.20M

FCF Per Share

Each share generates $-0.18 in free cash annually.

$-0.18

FCF Yield

NVCR converts -1.03% of its market value into free cash.

-1.03%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.61

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-4.29

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.07

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.95

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.69

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.89

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.44

vs 25 benchmark

ROA

Return on assets percentage

-0.19

vs 25 benchmark

ROCE

Return on capital employed

-0.27

vs 25 benchmark

How NVCR Stacks Against Its Sector Peers

MetricNVCR ValueSector AveragePerformance
P/E Ratio-13.6131.50 Better (Cheaper)
ROE-44.00%422.00% Weak
Net Margin-21.25%19867.00% Weak
Debt/Equity0.690.53 Weak (High Leverage)
Current Ratio2.895.56 Strong Liquidity
ROA-18.68%1571.00% Weak

NVCR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Novocure Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

20.03%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-722.70%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-144.78%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ